Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TNF
REST API REST API
Homo sapiens
TNF is differentially expressed in 214 experiments: 62 organism parts: lung, kidney, ... (60 more);, 96 disease states: normal, Burkitt's lymphoma, ... (94 more);, 81 cell types 199 cell lines 36 compound treatments and 59 other conditions.
Synonyms TNF-alpha, TNFA, DIF, TNFSF2
Orthologs tnfb (Danio rerio)   tnfa (Danio rerio)   TNFA_BOVIN (Bos taurus)   Tnf (Mus musculus)   Tnf (Rattus norvegicus)   tnf (Xenopus laevis)   TNFA_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term humoral immune response, plasma membrane, glucose metabolic process, positive regulation of nitric oxide biosynthetic process, sequestering of triglyceride, negative regulation of transcription, DNA-dependent, protein binding, apoptosis, response to salt stress, regulation of cell proliferation, intracellular, negative regulation of cell proliferation, extracellular space, embryonic digestive tract development, membrane, tumor necrosis factor receptor binding, protein import into nucleus, translocation, negative regulation of apoptosis, activation of caspase activity, extracellular region, positive regulation of MAP kinase activity, membrane raft, anti-apoptosis, response to hypoxia, cytokine activity, skeletal muscle contraction, external side of plasma membrane, positive regulation of JNK cascade, activation of MAPK activity, positive regulation of NFAT protein import into nucleus, recycling endosome, defense response to Gram-positive bacterium, identical protein binding, induction of apoptosis, defense response, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, positive regulation of protein complex assembly, negative regulation of viral genome replication, integral to plasma membrane, defense response to bacterium, regulation of protein secretion, immune response, response to drug, JNK cascade, integral to membrane, positive regulation of NF-kappaB transcription factor activity, regulation of I-kappaB kinase/NF-kappaB cascade, negative regulation of transcription from RNA polymerase II promoter, calcium-mediated signaling, cell surface, extracellular matrix organization, signal transduction, positive regulation of transcription, DNA-dependent, organ morphogenesis, activation of MAPKKK activity, response to mechanical stimulus, protease binding, positive regulation of heterotypic cell-cell adhesion, positive regulation of calcidiol 1-monooxygenase activity, positive regulation of I-kappaB kinase/NF-kappaB cascade, response to activity, negative regulation of glucose import, positive regulation of protein complex disassembly, positive regulation of peptidyl-serine phosphorylation, tumor necrosis factor-mediated signaling pathway, positive regulation of NF-kappaB import into nucleus, positive regulation of hair follicle development, positive regulation of translational initiation by iron, leukocyte migration, positive regulation of chronic inflammatory response to antigenic stimulus, positive regulation of ERK1 and ERK2 cascade, regulation of immunoglobulin secretion, necrotic cell death, induction of apoptosis via death domain receptors, positive regulation of cytokine production, positive regulation of chemokine biosynthetic process, positive regulation of cytokine secretion, positive regulation of humoral immune response mediated by circulating immunoglobulin, negative regulation of lipid catabolic process, positive regulation of synaptic transmission, chronic inflammatory response to antigenic stimulus, regulation of branching involved in salivary gland morphogenesis, positive regulation of interferon-gamma production, response to virus, negative regulation of branching involved in lung morphogenesis, positive regulation of necrotic cell death, positive regulation of protein transport, positive regulation of interleukin-6 production, negative regulation of lipid storage, positive regulation of vitamin D biosynthetic process, negative regulation of interleukin-6 production, negative regulation of fat cell differentiation, negative regulation of cytokine secretion involved in immune response, regulation of osteoclast differentiation, induction of necroptosis by extracellular signals, negative regulation of growth of symbiont in host, cellular extravasation, positive regulation of membrane protein ectodomain proteolysis, epithelial cell proliferation involved in salivary gland morphogenesis, inflammatory response, induction of apoptosis by extracellular signals, positive regulation of osteoclast differentiation, positive regulation of neuron apoptosis, leukocyte tethering or rolling, transformed cell apoptosis, positive regulation of smooth muscle cell proliferation, regulation of insulin secretion, negative regulation of L-glutamate transport, positive regulation of chemokine production, positive regulation of protein kinase B signaling cascade, cell activation, phagocytic cup, positive regulation of mitosis, response to glucocorticoid stimulus, osteoclast differentiation, receptor biosynthetic process, regulation of protein phosphorylation, positive regulation of protein phosphorylation, positive regulation of podosome assembly, positive regulation of fever generation, cellular response to amino acid stimulus, transcription regulatory region DNA binding, positive regulation of sequence-specific DNA binding transcription factor activity, cellular response to nicotine
InterPro Term TNF_family, TNF_a/b/c, TNF_alpha
Gene-Disease Assocation PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO, PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL, MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1, MALARIA, SUSCEPTIBILITY TO, HEPATITIS B VIRUS, SUSCEPTIBILITY TO, ASTHMA, SUSCEPTIBILITY TO
UniProt Accession B5BUQ6, B0V0H5, C1K3N5, P01375, Q5STB3
Search EB-eye ENSG00000232810
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-22541, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (30 experiments)

Factor Value U/D Experiments
HL-60
1
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
PC3
2
E-GEOD-5258, E-MEXP-2034
P3HR1
1
E-MTAB-37
SUM149PT
1
E-MTAB-62
NCIH1838
1
E-MTAB-37
CHP212
1
E-MTAB-37
193 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13987, ... (40 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
neutrophil
1
E-GEOD-12662
peripheral blood mononuclear cell
1
E-GEOD-3026
LCC
1
E-GEOD-19188
fibroblast
1
E-GEOD-3920
immature monocyte derived dendritic cell
1
E-GEOD-4984
75 more value(s).


Disease state

studied in E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-GEOD-2549, E-GEOD-9692, ... (32 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
acute promyelocytic leukemia
2
E-GEOD-96, E-MTAB-62
breast carcinoma
1
E-TABM-276
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
1
E-GEOD-3167
glioblastoma
1
E-GEOD-4290
ischemic cardiomyopathy
1
E-GEOD-1145
90 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
17beta-estradiol
3
2
E-GEOD-4006, E-GEOD-2292
lipopolysaccharide
2
3
E-TABM-868, E-MEXP-1958, E-GEOD-3140, E-GEOD-3720, E-GEOD-2706 ... (5 experiments)
control
1
2
E-GEOD-4006, E-GEOD-3284, E-GEOD-7664
interferon-gamma
1
E-GEOD-1432
granulocyte-colony stimulating factor
1
E-GEOD-7400
all-trans retinoic acid
1
E-GEOD-995
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-21340 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-6236, E-GEOD-4667, E-MEXP-958, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-TABM-147

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-MTAB-108 ... (5 experiments)

Genotype
studied in E-GEOD-17476, E-TABM-868, E-TABM-601, E-GEOD-17347, E-MEXP-1403 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-12773, E-GEOD-3003, E-MEXP-1446, E-GEOD-22278, E-MEXP-2146, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-GEOD-1926, E-MEXP-2069, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (6 experiments)

Karyotype
studied in E-GEOD-12662

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-3982, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-33562, E-GEOD-16193, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.369 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM